Form 8-K

8-K — Transcode Therapeutics, Inc.

Accession: 0001104659-26-075440

Filed: 2026-06-18

Period: 2026-06-18

CIK: 0001829635

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — tm2618153d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2618153d1_ex99-1.htm)

GRAPHIC (tm2618153d1_ex99-1img001.jpg)

GRAPHIC (tm2618153d1_ex99-1img002.jpg)

GRAPHIC (tm2618153d1_ex99-1img003.jpg)

GRAPHIC (tm2618153d1_ex99-1img004.jpg)

GRAPHIC (tm2618153d1_ex99-1img005.jpg)

GRAPHIC (tm2618153d1_ex99-1img006.jpg)

GRAPHIC (tm2618153d1_ex99-1img007.jpg)

GRAPHIC (tm2618153d1_ex99-1img008.jpg)

GRAPHIC (tm2618153d1_ex99-1img009.jpg)

GRAPHIC (tm2618153d1_ex99-1img010.jpg)

GRAPHIC (tm2618153d1_ex99-1img011.jpg)

GRAPHIC (tm2618153d1_ex99-1img012.jpg)

GRAPHIC (tm2618153d1_ex99-1img013.jpg)

GRAPHIC (tm2618153d1_ex99-1img014.jpg)

GRAPHIC (tm2618153d1_ex99-1img015.jpg)

GRAPHIC (tm2618153d1_ex99-1img016.jpg)

GRAPHIC (tm2618153d1_ex99-1img017.jpg)

GRAPHIC (tm2618153d1_ex99-1img018.jpg)

GRAPHIC (tm2618153d1_ex99-1img019.jpg)

GRAPHIC (tm2618153d1_ex99-1img020.jpg)

GRAPHIC (tm2618153d1_ex99-1img021.jpg)

GRAPHIC (tm2618153d1_ex99-1img022.jpg)

GRAPHIC (tm2618153d1_ex99-1img023.jpg)

GRAPHIC (tm2618153d1_ex99-1img024.jpg)

GRAPHIC (tm2618153d1_ex99-1img025.jpg)

GRAPHIC (tm2618153d1_ex99-1img026.jpg)

GRAPHIC (tm2618153d1_ex99-1img027.jpg)

GRAPHIC (tm2618153d1_ex99-1img028.jpg)

GRAPHIC (tm2618153d1_ex99-1img029.jpg)

GRAPHIC (tm2618153d1_ex99-1img030.jpg)

GRAPHIC (tm2618153d1_ex99-1img031.jpg)

GRAPHIC (tm2618153d1_ex99-1img032.jpg)

GRAPHIC (tm2618153d1_ex99-1img033.jpg)

GRAPHIC (tm2618153d1_ex99-1img034.jpg)

GRAPHIC (tm2618153d1_ex99-1img035.jpg)

GRAPHIC (tm2618153d1_ex99-1img036.jpg)

GRAPHIC (tm2618153d1_ex99-1img037.jpg)

GRAPHIC (tm2618153d1_ex99-1img038.jpg)

GRAPHIC (tm2618153d1_ex99-1img039.jpg)

GRAPHIC (tm2618153d1_ex99-1img040.jpg)

GRAPHIC (tm2618153d1_ex99-1img041.jpg)

GRAPHIC (tm2618153d1_ex99-1img042.jpg)

GRAPHIC (tm2618153d1_ex99-1img043.jpg)

GRAPHIC (tm2618153d1_ex99-1img044.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2618153d1_8k.htm · Sequence: 1

false

0001829635

2026-06-18

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event

reported): June 18, 2026

TRANSCODE

THERAPEUTICS, INC.

(Exact name of registrant as specified in its

charter)

Delaware

001-40363

81-1065054

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

TransCode

Therapeutics, Inc.

Liberty Square, #2382

Boston, Massachusetts

02109

(Address

of principal executive offices, including zip code)

(857)

837-3099

(Registrant’s

telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since

Last Report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR

240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR

240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act.

Title of each class

Trading symbol(s)

Name of each exchange on which

registered

Common

Stock, par value $0.0001 per share

RNAZ

The Nasdaq

Capital Market

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2

of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging

growth company x

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01

Regulation FD Disclosure.

Press Release

On June 18, 2026, TransCode Therapeutics, Inc.,

a Delaware corporation (the “Company”) posted a presentation to its website that may be used by the Company from time to time

with investors, analysts, collaborators, vendors or other third parties. A copy of the presentation is furnished as Exhibit 99.1 to this

Current Report on Form 8-K.

The information in Item 7.01 of this Current Report

on Form 8-K, including the information in the presentation attached as Exhibit 99.1 to this Current Report on Form 8-K, is furnished pursuant

to Item 7.01 of Form 8-K and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of

1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section. Furthermore, the information

in Item 7.01 of this Current Report on Form 8-K shall not be deemed to be incorporated by reference in the filings of the Company under

the Securities Act of 1933, as amended.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number

Description

99.1

Presentation,

dated June 18, 2026 (furnished herewith)

104

Cover

Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)

SIGNATURES

Pursuant to the requirements

of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto

duly authorized.

TRANSCODE THERAPEUTICS, INC.

By:

/s/ Philippe Calais

Name:

Philippe Calais

Title:

Chief Executive Officer

June 18, 2026

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2618153d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

Three Platforms, One Mission:

Transforming Advanced Cancer Care

NASDAQ: RNAZ

Company Forward Looking Statement

Before you invest in the securities of TransCode Therapeutics, Inc. (“TransCode” or the “Company”), you should read TransCode’s filings

with the U.S. Securities and Exchange Commission (“SEC”) for more complete information about the Company. You can obtain these

documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, the Company will send you these documents at

no charge if you request them from TransCode at 6 Liberty Square, #2382, Boston, MA 02109, Attention: Investor Relations; or by calling

(857) 837-3099.

This presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall TransCode make any sale of its securities,

in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the

securities laws of any such state or other jurisdiction.

Statements in this presentation contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking

statements contained in this presentation may be identified by use of words such as “anticipate,” “believe,” “could”, “estimate,”

“expect,” “forecast,” “may,” “outlook,” “project,” “should,” “will,” or other similar words, and include, without limitation, statements

regarding the Company’s expectations regarding current or future clinical trials, research programs, and financial results including that the

Company requires substantial additional capital. Forward-looking statements are based on the Company’s current expectations and are

subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based

on assumptions as to future events that may not prove to be accurate, including that clinical trials may be delayed; that reported trial

data may be preliminary or that interim data may be superseded by subsequent data obtained from the same clinical trial or in

connection with other and/or subsequent clinical trials; and that any anticipated meetings with or presentations to the U.S. Food and Drug

Administration (“FDA”) may be delayed, may not occur at all, or may not result in outcomes that the Company prefers. These and other

risks and uncertainties are described more fully in the sections titled “Risk Factors” and "Cautionary Note Regarding Forward-Looking

Statements” in the Company’s Annual Report on Form 10-K filed annually with the SEC, and in other reports subsequently filed with the

SEC. Forward-looking statements contained in this presentation are made as of the date of this presentation; the Company undertakes no

duty to update such information except as required under applicable law.

A Rare Small-Cap with Three Near Term Catalysts

Harvard-faculty founders Massachusetts General Hospital (MGH) /Harvard Medical School (HMS) to target

advanced cancers

Since the Company’s initial public offering in 2021, ~$100 million net invested to date through financings and

grants; no long-term debt

Pioneering complementary approaches aimed at redefining the boundaries of advanced cancer care:

RNA-targeted therapeutics that precisely reach tumors: prioritized

Vaccine immunotherapies that mobilize the immune system to recognize and destroy cancer cells

Immuno-oncolytic agents that directly target tumors while simultaneously stimulating systemic

immune responses

Critical Need for Effective Therapies Targeting Advanced Cancer

Cancer Deaths Due to Advanced Disease

>90%

Advanced Cancer

Reduces 5-year Survival

Key Challenge to Treatment

Dissemination to distant sites, immune

evasion, resistance

Global Market by 2032*

$120-$250B

*Source: 2019 American Cancer Society, Inc., Surveillance Research; International Agency for Research on Cancer in its report named GLOBOCAN 2022: Precedence Research January 2022

Low Survival if Diagnosed at Advanced Stage

Experienced Management

Tom Fitzgerald, MBA

CFO; Director

Zdravka Medarova, PhD

Cofounder, CSO

Susan Duggan, RN, MBA

SVP Operations

Tania Montgomery

VP Business Development

Philippe P Calais, PharmD PhD

CEO, Chairman of the Board

Michel Janicot, PhD

Consulting Head

Translational Science

Daniel Vlock, MD

Consulting

Oncology Clinician

Lou Brenner, MD

Consulting Clinical and

Strategic Advisor

Leading Advisors with Oncology and RNA Expertise

Keith Flaherty, MD

Professor of Medicine &

Director of Clinical Research

Mass General Cancer Center

Lubo Nechev, PhD

Chief CMC Officer,

Alnylam Pharmaceuticals

Dejan Juric, MD

Director, Termeer Center for

Targeted Therapies

Massachusetts General Hospital

Director, Institute for RNA Medicine,

Beth Israel Deaconess Medical Center

Philip D Zamore, PhD

Founder, Alnylam and City Therapeutics,

Professor of Biomedical Sciences at the

University of Massachusetts Chan Medical

School

Anna Moore, PhD

Chair

TransCode Co-Founder;

Director, Precision Health

Program at Michigan State

University

Frank Slack, PhD

Board of Directors

Magda Marquet, PhD

Director

Erik Manting, PhD

Director

Philippe P Calais, PhD

Chairman and CEO

Elizabeth Czerepak, MBA

Director

Tom Fitzgerald, MBA

Director and CFO

Scientific Advisory Board

Co-CEO, ALMA Life Sciences

CEO, Mendus AB

CFO, Mirror Biologics

Jack E Stover

Director

Chairman of Board, Traws Pharma

Innovative and Differentiated Pipeline

TTX-MC138

Lead Therapeutic Candidate

AntagomiR targeting microRNA-10b

Phase 2a active

TTX-MC138

TWIST1

TTX-MC138 miR-10b

NF1

ROCK

cJUN

HOXD10

E-Cadherin

TBX5

PTEN

AKT

Select miR-10b Molecular Pathways

RHOC

Key Components

of Tumor

Invasion and

Metastases

Immune evasion

Tumor cell motility & metastasis

Anti-apoptosis & cell proliferation

Improved self-renewal:

Proliferation, apoptosis & growth

Type: Nucleic acid-based therapeutic designed to bind

to a specific microRNA and block its function

Tumor

Uptake: Specifically designed to promote tumor uptake

Target: MicroRNA-10b, a master regulator of metastatic

cancer

MoA: Inhibiting microRNA-10b blocks multiple cancer

pathways

Status: Phase 2a - relapsed refractory solid tumors and

micro-metastases

Iron oxide nanoparticle platform designed for

the delivery of RNA therapeutics to tumors

Clinical Development Plan: Metastatic Disease

Phase 1a

Dose escalation, all

comers, advanced solid

tumors

Phase 0

Microdose radiolabelled,

advanced solid tumors

Phase 2a

Dose expansion

Micrometastatic disease

Phase 2

First indication TBD

Phase 0 Phase 1a Phase 2a Phase 2

Indications: Advanced solid tumors

Design: Bayesian Optimal Interval (BOIN)

Endpoints: Safety & PK

Status: 16 treated

Results: No DLT’s, preliminary results

pending; 3 patients remain on trial

Indications: Stage 1-3 colorectal adenocarcinoma

with molecular disease (ctDNA positive)

following standard therapy with curative intent

Design: Single Cohort, N = Up to 45

Endpoints: RFS, DOR, PFS, Clearance ctDNA

Status: enrolling

Indications: Pending Phase 2a results

Design: Double blind, RCT, Adaptive Design

(N= 50 - 200)

Endpoints: TBD

Status: Following Phase 2a completion

2023 2024 2025 2026 2027 2028

Completed Completed Ongoing In Planning

Indications: Advanced solid tumors

Design: Single Cohort

Endpoints: Target Engagement,

Safety & PK

Status: 1 treated

Results: Delivery confirmation

Phase 0: Accumulation in Metastatic Lesions Confirmed

• Dosed 1 female patient with stage-IV

metastatic breast cancer (metastatic

sites: bone, liver and lungs – left panel)

• Single sub-therapeutic dose of labelled

TTX-MC138

• PET-MRI performed at 2, 3, 6 and 24

hours post-dosing (right panel)

• Showed accumulation of the

drug in the metastatic lesions

• Well-tolerated

[64 [ -Cu]-labelled TTX-MC138 18F]-labelled fluorodeoxyglucose (FDG)

A single microdose (90 µg) of 64Cu-labelled TTX-MC138 (mCi) by intravenous bolus on Day 1

Pre-Dosing Post-Dosing

Phase 1a Trial: Overview and Status

Dose escalation, 4 cohorts of 3 + patients

Advanced solid tumors, all comers

Objectives Endpoints

Primary Objectives Primary Endpoint

Evaluate safety and

tolerability, determine

MTD and select RP2D

Incidence of TEAEs*

Secondary Objectives Secondary

Endpoints

Evaluate anti-tumor

activity

ORR, DCR, DoR, PFS,

OS**

Phase 1A Highlights*

# Subjects Treated 16

# Doses to Date ~ 86

Median Duration ~ 5 Months

Longest Duration 15 Doses (Months)

DLT’s 0

Patients still on Study 3

End of Phase 1A (Safety) December 2025

* Treatment Emergent Adverse Events

** Objective Response Rate, Disease Control Rate,

Duration of Response, Progression-Free Survival,

Overall Survival

*Preliminary information. Data analysis and review are

ongoing as 3 patients remain on study

Achieved

Analysis ongoing;

3 patients remain on study

Phase 1a Trial: Subject Tumor Type

Subject # Dose Level Type of cancer diagnosed Location

100-003 0.8 mg/kg Malignant neoplasm of endometrium Uterus

103-001 0.8 mg/kg Solitary fibrous tumor (hemangiopericytoma) Right forehead

100-002 0.8 mg/kg Adenocarcinoma of the rectum Rectum

100-004 1.6 mg/kg Malignant neoplasm of sigmoid colon Sigmoid colon

102-001* 1.6 mg/kg Dose Escalated

to 3.2mg/kg Extraskeletal myxoid chondrosarcoma Soft tissue

100-005 1.6 mg/kg Olfactory neuroblastoma Nasal cavity

103-002 3.2 mg/kg Adenoid cystic carcinoma Right maxillary sinus

101-001 3.2 mg/kg Myxoid sarcoma Soft tissue

102-002 3.2 mg/kg Adenocarcinoma of the breast Breast

100-007 4.8 mg/kg Leiomyosarcoma of retroperitoneum Right hepatic lobe

103-003* 4.8 mg/kg Carcinoma thyroid gland Papillary thyroid carcinoma

103-004 4.8 mg/kg Renal cell carcinoma Left kidney

100-008* 3.2mg/kg (BF) Adenoid cystic carcinoma Lung

102-003 3.2mg/kg (BF) P16 positive, poorly differentiated squamous cell

carcinoma of the anterior right anal rectal junction Anus

100-009 3.2mg/kg (BF) Mucinous adenocarcinoma of sigmoid colon Gastrointestinal tract, lower

103-007 3.2mg/kg (BF) Adenocarcinoma pancreas Pancreas

* Patients remaining in the study

Phase 1a Trial: Safety Primary Endpoint

Cohort Dose Number of Patients DLT’s

1 0.8mg/kg 3 0

2 1.6mg/kg 3 0

3 3.2mg/kg 6 0

4 4.8mg/kg 3 0

Treatment Related Serious Adverse Events (SAE)

SAE

# Subjects

(N=16) % Subjects Grade

Infusion

Reaction*

1 6.25% 2

* SAE due to hospitalization observation several hours post treatment

• TTX-MC138 demonstrated strong tolerability

• No dose-limiting toxicities (DLT’s) observed at all dose levels

• No clinically significant treatment-related safety signals identified

• Dose escalation completed through 4.8 mg/kg without limitation

Phase 1a Trial: Safety Overview

Adverse Events

Adverse Event

(Maximum CTCAE Grade) Total (N=16)

Nausea 2 (12.5%)

Grade 1 2 (12.5%)

Hyponatremia 3 (18.8%)

Grade 2 1 (6.3%)

Grade 1 2 (12.5%)

Iron overload 2 (12.5%)

Grade 1 1 (6.3%)

Grade 3* 1 (6.3%)

Back pain 3 (18.8%)

Grade 1 3 (18.8%)

Dyspnea 3 (18.8%)

Grade 2 1 (6.3%)

Grade 1 2 (12.5%)

Pruritus 3 (18.8%)

Grade 1 3 (18.8%)

Subjects were counted once for each category at the highest severity grade.

*Elevated ferritin level, no organ damage reported

Adverse Event Frequency

• 62.5% of patients experienced at least one treatment-related adverse event

Severity of Adverse Events

• Most adverse events were Grade 1 or Grade 2,

indicating a tolerable safety profile

Common Affected Systems

• Metabolism, musculoskeletal, and respiratory systems

were most frequently observed

Grade 3 and Higher Events

• Grade 3 or higher adverse events were rare and did

not indicate emerging safety concerns

Phase 1a Trial: Pharmacokinetic Results

Pharmacokinetic profile from the analysis of plasma from patients receiving TTX-MC138

demonstrated evidence of drug availability consistent with preclinical data

Mean concentrations on C1D1 Supra-proportional Dose and AUC

Phase 1a Trial: Efficacy Analysis

Best Overall Response Evaluable Subjects (N=14)

Complete Response 0 (0%)

Partial Response 0 (0%)

Stable Disease 9 (64.3%)

Progressive Disease 3 (21.4%)

Not Evaluable 2 (14.3%)

Overall Response Rate

Swimmers Plot Response Categories

Durable disease stabilization in 9 out of 14 (64%) evaluable

metastatic patients consistent with the anticipated cytostatic

mechanism of miR-10b suppression

Progression-free survival, overall safety population

6 months

Source: Table 14.2.1.1.1 dated 3/14/2026

Phase 1a Trial: Thyroid Cancer Case

Patient 103-003 with metastatic thyroid cancer

with lung metastases

Thyroglobulin levels

• Associated with increased tumor burden

• Dropped to 0 after 6 cycles

• Stable disease radiographically

C7 and C8 Dose held

• Possibly related to elevated TSAT/Ferritin levels

Patient remains on treatment

Patient 103-003 Thyroglobulin levels

Phase 2a Trial: TTX-MC138 in Colorectal Cancer

Targeting minimal residual disease

Opportunity: Address unmet medical need by evaluating TTX-MC138 in colorectal patients post adjuvant treatment with

curative intent

Mechanism of Action: Evaluate TTX-MC138 in micrometastatic

setting where no options exist for patients

Treatment: TTX-MC138 can effectively intercept the metastatic

process in patients with micrometastases at risk for recurrence

Safety Profile: TTX-MC138 is well tolerated with minimal

adverse events noted. Important in patients who have

completed aggressive and toxic adjuvant therapy

Therapeutic Intervention: May have the greatest opportunity

to improve long-term outcomes in patients

Partnership with QLHC: PRE-I-SPY clinical trial platform

“Liquid Biopsies”

Detection of Microscopic Disease: A Diagnostic Shift

• ctDNA able to detect microscopic disease far below limits

of detection of radiologic procedures

• Strong correlation between detection of ctDNA and

development of radiologic recurrence

• Presents a new therapeutic opportunity

• Ability to select patients at a high risk of recurrence following

conventional primary and adjuvant therapy given with

curative intent

TTX-MC138’s mechanism of action and safety

profile make it uniquely suited for use in this setting

Phase 2a Study: Quantum Leap Healthcare Collaboration

Accelerate Success - Partnership with the Quantum Leap Healthcare

Collaborative oncology platform study

Rapid Study Initiation - Ready-to-deploy infrastructure and parallel

regulatory approvals enable swift clinical study activation

Leverage Established Clinical Network - Leading clinical research

centers with experienced investigators who help define standard-of-care practices

Operational Efficiency - Lean operational model minimizes

administrative overhead while ensuring high-quality trial execution

Accelerated Timelines and Cost Savings - Fast onboarding and

implementation enable quicker patient enrollment and reduced

development costs

Platform Study PI:

Dr. Paula Pohlmann, MD (MD Anderson)

Planned Clinical Sites

• Mayo (MN, FL, AZ)

• Univ. of Minnesota

• Univ. of Alabama

• Univ. of Chicago

• Rutgers

• The Ohio State

• U. Penn

• NYU Langone

• MGH

Phase 2a Trial Design: Single Arm Open Label

Patient Selection

ctDNA+ after curative-intent standard therapy

ctDNA Monitoring

Serial ctDNA analysis every cycle

(primary endpoint assessment)

Response Assessment

ctDNA clearance →MRD Negativity, MRD

Conversion, Depth of MRD Response

Readout

May support registration trial design

First-mover in CRC / MRD space

Treatment

N = 45 patients, 4.8 mg/kg, IV, Q28D, 12 cycles

Seviprotimut-L

Cancer Vaccine

Seviprotimut-L: Overview and Unmet Needs

• FDA “Orphan Drug” status

• Successful completion of adaptive Phase 3

clinical trial “MAVIS”

• FDA “Fast Track” designation

• Peer reviewed publication (JITC)

• Planned Phase 3 (“MELISSA”) potential for

confirmatory trial ⎼ FDA Special Protocol

Assessment (SPA)

• Manufacturing planning ongoing

Novel polyvalent shed antigens vaccine for the adjuvant treatment of Stage IIB and IIC melanoma

in patients 60 years and younger

• Keytruda (Merck) & Opdivo (BMS) are checkpoint inhibitors (CPIs) approved

for the adjuvant treatment of melanoma in Stage IIB and IIC patients at risk

for disease recurrence

• Seviprotimut-L clinical opportunities relative to CPIs:

• Potential to reduce risk of severe, long-term or chronic side effects from

immunotherapy

• Potential to lower cost – product manufacturing and different treatment

paradigm

• Broaden patient eligibility – Estimated < 50% of patients respond to CPIs,

patient selection methods (e.g., PD-L1 expression) are not reliable

• May be administered without affecting CPIs efficacy, first-line or in combination

• Oncologist and Dermatologist friendly, vaccine administration regimen

Seviprotimut-L: Phase 3 MAVIS Clinical Trial Design & Efficacy Results

Study Drug

• 40 µg seviprotimut* vs placebo

Study Population

• Ages 18 to 80, female and male

• Stage IIB/IIC, IIIA, and IIIB/IIIC melanoma patients, resected with clear margins

• Resection within 90 days of first dose

• No other biological modifiers within 60 days of first dose

Administration and Schedule

• Intradermally - 4 injections (0.2 mL each injection) 15 Doses over 24 months

Clinical Trial Sites

• 55 sites in US and Canada

* 0.8 mL suspension containing 0.05 mg/mL drug substance – shed antigens – plus 20 mg/mL alum in 0.9% saline

Recurrence-Free Survival

Overall Survival

Planned subgroup analysis (N = 111) revealed trends to longer:

• RFS (HR 0.65 [0.37,1.17])

• OS (HR 0.37[0.13, 1.06])

Journal Immunother Cancer,2021 Oct 1; 9 (10)

Pre-Clinical Programs

UIO 524

Next Generation Oncolytic Virus

Next Generation Oncolytic Virus: UIO-524

High lytic capacity, immunogenicity, selective replication and manufacturing scale up

UIO-524: engineered adenovirus type 5 based oncolytic virus

• Hybrid promoter (SPARC-KR) to drive stromal-tumor

specific virus replication

• Armed with three powerful immunostimulatory genes

(CD40L, 4-1BBL and IL-21)

• Engineered to target a tumor cell receptor, desmoglein-2,

highly expressed in multiple cancer indications

• Expected low risk, scalable manufacturing

• Preclinical development stage (currently halfway through

IND)

• Earlier stage oncolytic viruses (UIO-525 and UIO-526) in

company pipeline

UIO 524: Preclinical PoC & Initial Focus for Clinical Development

7 14 21 28

400

800

1200

1600

Human A549 NSCLC

(immuno-compromised mice)

Tumor Volume ( mm3 )

Days

PBS

UIO-524

Significant oncolytic activity demonstrated

with UIO-524 in experimental tumor model

Low grade Muscle Invasive Bladder Cancer (MIBC)

• Bladder cancer 9th most common cancer globally

(heavily concentrated in men and older adults)

• Oncolytic viruses are emerging as novel bladder

cancer immunotherapies, with intravesical delivery

allowing high local exposure with limited potential

systemic toxicity

Relevant Competitive drugs (similar therapeutic modality):

− CG-Oncology’s CG0070 (cretostimogene): modified, replication-competent adenovirus engineered

to carry a GM-CSF transgene

− Binhui Biopharm’s OH2 :recombinant oncolytic virus derived from a genetically modified herpes

simplex virus type 2 strain) armed with genes like IL-21 and 4-1BBL

• Muscle-invasive bladder cancer (MIBC) means the

tumor has grown into the thick detrusor muscle

layer of the bladder wall

UIO-524 represents a novel therapeutic modality for bladder cancer, with significant opportunity to successfully

develop UIO-524 for the treatment of adult patients with low-grade MIBC

TTX Drug Design Engine

TTX Tunable Drug Design Engine

Payload diversity

Size

Smart release linkers

Enhanced targeting

Nanometers Microns

Non-cleavable pH sensitive Tissue-specific Time-sensitive

Polymers Biomolecules (e.g. glucose) mAbs Peptides

Tunable

Platform

Customizable to

desired size,

payload and

pharmacokinetics

Smart Release

Technology

Allows payload to

bind to/ release from

carrier inside cells

according to

specifications

Desirable Carrier

Attributes

Highly stable,

low toxicity, low

immunogenicity

Payload

Diversity

Allows packaging of

nucleic acids,

proteins, peptides,

radionuclides, small

molecules

Enhanced Targeting

and Uptake

Greatly improved

tumor uptake and

entrapment in tumor

cells

Nucleic acids Peptides Radionuclides Small Molecules

Customized according to predesigned

specifications

Versatile platform for internal use, also available for partnering

TTX-siPD-L1

RNAi-based Checkpoint Inhibitor

Traditional ICI* vs TTX-siPD-L1: Mechanistic & Clinical Comparison

Properties Traditional ICI* TTX-siPD-L1

Mechanism Blocks PD-1/PD-L1 interaction at the cell

surface

siRNA silences PD-L1 gene expression inside tumor cells

Targeting Systemic immune activation; broad

exposure

Tumor-targeted delivery; preferential uptake by tumor

microenvironment and reduced systemic immune activation

Pharmacology Long-acting antibodies; fixed systemic

distribution

siRNA with controlled intracellular release;

potential for tunable PD-L1 knockdown which may overcome

resistance driven by PD-L1 overexpression

Efficacy Best in “hot” tumors; resistance common May convert “cold” tumors to “hot” by reducing

immunosuppression; potential in ICI-resistant disease

Safety Higher risk of immune-related toxicities Lower systemic immune activation driven by TTX

biodistribution

TTX-siPD-L1 suppresses PD-L1 production at the genetic level with tumor-targeted

delivery—offering a potentially safer, more adaptable approach

* Immune Checkpoint Inhibitors

TTX-siPD-L1 Generated Robust Preclinical Response in Mice

Results:

• High-dose TTX-siPD-L1 + gemcitabine regressed

pancreatic tumors by 90% within the first two weeks of

treatment and delayed tumor growth. (Figure A above)

• Treatment increased survival - 67% of the experimental

animals survived for 12 weeks. (Figure B above)

90% tumor regression in the first two weeks of treatment

Source: Scientific Reports, 9 (1), 4712 2019

TTX-RIGA

A PRR Agonist

TTX-RIGA: RIG-I Signaling

Properties Traditional ICI* TTX-RIGA

Mechanism Activate RIG-I broadly, often requiring

high doses

Tumor-targeted RIG-I activation via nanoparticle

delivery and template-based activation

Targeting Limited tumor selectivity; need for

local injection

Preferential activation in tumors; minimizes systemic

innate activation

Delivery Often unstable RNA ligands; rapid

degradation

Stabilized RNA agonist protected within nanoparticles

Efficacy Potent but short-lived signaling;

toxicity limits dosing

Sustained RIG-I signaling; enhances antigen

presentation and T-cell priming

Safety High risk of cytokine storm, flu-like

symptoms, systemic inflammation

Reduced cytokine-related toxicity; improved

therapeutic window

Traditional RIG-I agonists activate innate immunity system-wide, limiting dose and safety.

TTX-RIGA delivers a stabilized RIG-I agonist selectively activated in tumors, enabling potent local immune

activation with reduced systemic toxicity

* Immune Checkpoint Inhibitors

TTX-RIGA: In Vivo Efficacy

C57BL/6 mice were implanted s.c. with B16-F10 cells. Treatment was initiated once tumors were established.

Treatment continued until day 6 after tumor implantation. On day 12 after the beginning of treatment, a secondary

tumor challenge with the same cell line was performed by s.c. implantation into the contralateral flank.

TTX Pre-Clinical Programs: Moving Forward

• Developing nucleic acid-based therapeutics against cancer depends critically on successful

delivery to tumors and metastases

• TTX has shown successful delivery to cancerous lesions, including in humans

• The efficacy of TTX-based nucleic acid therapeutics, e.g. TTX-siPD-L1, reflects effects both on the

tumor cells and tumor microenvironment, especially macrophages

• PRR agonism holds promise for the treatment of cancer with reports of immunity against

rechallenge in animals

• Systemic approaches to agonize PRR, including RIGA, could unlock the potential of the approach

against cancer by potentially allowing safe application in the context of disseminated disease

Corporate Finance Overview

Recent Corporate Developments

Q4 25 Q1 26 Q2 26

Acquisition of Polynoma

Series A Pref.

$25 million investment by

CK Life Sciences

Series B Pref.

Licensing of immuno-oncolytic portfolio from

Unleash Immuno Oncolytics

Series C Pref.

$20 million SEPA

transaction with

Yorkville Advisors

Conv. Notes

Common Stock

Capital Structure

Share Price June 11, 2026 $5.69

Shares Outstanding (000) * June 11, 2026 950

Market Capitalization ($mm) June 11, 2026 $5.4

Shares Outstanding (000) * Pro Forma 18,655

Market Capitalization ($mm) Pro Forma $106.1

Long-Term Debt Mar 31, 2026 - - -

Cash & Equivalents ($mm) Mar 31, 2026 $12.8

* Excludes 543,270 warrants and 2,035 options with per share exercise prices of $272.71 and $16,958.12, respectively

Pro Forma information reflects full conversion of Series A, B and C preferred shares into common stock

Investment Thesis

"We have built a three-platform oncology

company with a pipeline

that would cost multiples

of our current market cap

to replicate from scratch.

That gap closes with

execution."

Philippe P. Calais, CEO

Building an innovative and differentiated oncology company to meaningfully improve the

treatment of advanced cancer by developing breakthrough treatment modalities acting on

metastatic cancer and enhancing the power of the immune system

Strategic focus

• Balanced and scalable portfolio: “3 shots on goal”

• Near term clinical value creation and benefit for the patients

• Platform driven innovation and long-term pipeline sustainability

• Prioritize TTX-MC138 clinical development

• Three potential catalysts in the next 18 months: Phase 2a enrolment

completion, preliminary data readout, final data

• Pipeline built for differentiation and scale

• Combination treatment of Seviprotimut-L and TTX-MC138

• Explore the potential of our TTX proprietary delivery engine

• Develop UIO524

• Organization and capital discipline

• Execution

• Recent transactions structured to avoid heavy upfront financial commitment

• Communication

Near Term Catalysts – Each a Potential Inflection Point

Q2 26 Q3 26 Q4 26 1H 27 2H27

TTX-MC138

Phase 2a

enrollment

initiation

TTX-MC138

Phase 2a

enrollment

update

TTX-MC138

Phase 2a

preliminary

results

TTX-MC138

Phase 1a

results at

major oncology

conference

Phase 2a

enrollment

completion

TTX-MC138

Phase 2a

completion,

preliminary

readout

Advance other

preclinical

assets towards

IND*

* Assumes available funding, incl. government grants

GRAPHIC

Filename: tm2618153d1_ex99-1img001.jpg · Sequence: 6

Binary file (88360 bytes)

Download tm2618153d1_ex99-1img001.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img002.jpg · Sequence: 7

Binary file (256693 bytes)

Download tm2618153d1_ex99-1img002.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img003.jpg · Sequence: 8

Binary file (125869 bytes)

Download tm2618153d1_ex99-1img003.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img004.jpg · Sequence: 9

Binary file (116492 bytes)

Download tm2618153d1_ex99-1img004.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img005.jpg · Sequence: 10

Binary file (115038 bytes)

Download tm2618153d1_ex99-1img005.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img006.jpg · Sequence: 11

Binary file (118084 bytes)

Download tm2618153d1_ex99-1img006.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img007.jpg · Sequence: 12

Binary file (78800 bytes)

Download tm2618153d1_ex99-1img007.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img008.jpg · Sequence: 13

Binary file (42969 bytes)

Download tm2618153d1_ex99-1img008.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img009.jpg · Sequence: 14

Binary file (129900 bytes)

Download tm2618153d1_ex99-1img009.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img010.jpg · Sequence: 15

Binary file (146634 bytes)

Download tm2618153d1_ex99-1img010.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img011.jpg · Sequence: 16

Binary file (137951 bytes)

Download tm2618153d1_ex99-1img011.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img012.jpg · Sequence: 17

Binary file (127067 bytes)

Download tm2618153d1_ex99-1img012.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img013.jpg · Sequence: 18

Binary file (154912 bytes)

Download tm2618153d1_ex99-1img013.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img014.jpg · Sequence: 19

Binary file (113172 bytes)

Download tm2618153d1_ex99-1img014.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img015.jpg · Sequence: 20

Binary file (141189 bytes)

Download tm2618153d1_ex99-1img015.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img016.jpg · Sequence: 21

Binary file (111775 bytes)

Download tm2618153d1_ex99-1img016.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img017.jpg · Sequence: 22

Binary file (111351 bytes)

Download tm2618153d1_ex99-1img017.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img018.jpg · Sequence: 23

Binary file (93547 bytes)

Download tm2618153d1_ex99-1img018.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img019.jpg · Sequence: 24

Binary file (196271 bytes)

Download tm2618153d1_ex99-1img019.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img020.jpg · Sequence: 25

Binary file (141382 bytes)

Download tm2618153d1_ex99-1img020.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img021.jpg · Sequence: 26

Binary file (83766 bytes)

Download tm2618153d1_ex99-1img021.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img022.jpg · Sequence: 27

Binary file (25693 bytes)

Download tm2618153d1_ex99-1img022.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img023.jpg · Sequence: 28

Binary file (151397 bytes)

Download tm2618153d1_ex99-1img023.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img024.jpg · Sequence: 29

Binary file (152562 bytes)

Download tm2618153d1_ex99-1img024.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img025.jpg · Sequence: 30

Binary file (25574 bytes)

Download tm2618153d1_ex99-1img025.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img026.jpg · Sequence: 31

Binary file (26173 bytes)

Download tm2618153d1_ex99-1img026.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img027.jpg · Sequence: 32

Binary file (129427 bytes)

Download tm2618153d1_ex99-1img027.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img028.jpg · Sequence: 33

Binary file (176704 bytes)

Download tm2618153d1_ex99-1img028.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img029.jpg · Sequence: 34

Binary file (27230 bytes)

Download tm2618153d1_ex99-1img029.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img030.jpg · Sequence: 35

Binary file (131500 bytes)

Download tm2618153d1_ex99-1img030.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img031.jpg · Sequence: 36

Binary file (27861 bytes)

Download tm2618153d1_ex99-1img031.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img032.jpg · Sequence: 37

Binary file (155059 bytes)

Download tm2618153d1_ex99-1img032.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img033.jpg · Sequence: 38

Binary file (128463 bytes)

Download tm2618153d1_ex99-1img033.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img034.jpg · Sequence: 39

Binary file (21677 bytes)

Download tm2618153d1_ex99-1img034.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img035.jpg · Sequence: 40

Binary file (162997 bytes)

Download tm2618153d1_ex99-1img035.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img036.jpg · Sequence: 41

Binary file (127612 bytes)

Download tm2618153d1_ex99-1img036.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img037.jpg · Sequence: 42

Binary file (112140 bytes)

Download tm2618153d1_ex99-1img037.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img038.jpg · Sequence: 43

Binary file (25376 bytes)

Download tm2618153d1_ex99-1img038.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img039.jpg · Sequence: 44

Binary file (69405 bytes)

Download tm2618153d1_ex99-1img039.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img040.jpg · Sequence: 45

Binary file (87824 bytes)

Download tm2618153d1_ex99-1img040.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img041.jpg · Sequence: 46

Binary file (22353 bytes)

Download tm2618153d1_ex99-1img041.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img042.jpg · Sequence: 47

Binary file (152729 bytes)

Download tm2618153d1_ex99-1img042.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img043.jpg · Sequence: 48

Binary file (84434 bytes)

Download tm2618153d1_ex99-1img043.jpg

GRAPHIC

Filename: tm2618153d1_ex99-1img044.jpg · Sequence: 49

Binary file (64381 bytes)

Download tm2618153d1_ex99-1img044.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 51

v3.26.1

Cover

Jun. 18, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jun. 18, 2026

Entity File Number

001-40363

Entity Registrant Name

TRANSCODE

THERAPEUTICS, INC.

Entity Central Index Key

0001829635

Entity Tax Identification Number

81-1065054

Entity Incorporation, State or Country Code

Entity Address, Address Line One

Liberty Square

Entity Address, Address Line Two

#2382

Entity Address, City or Town

Boston

Entity Address, State or Province

Entity Address, Postal Zip Code

02109

City Area Code

857

Local Phone Number

837-3099

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, par value $0.0001 per share

Trading Symbol

RNAZ

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration